These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 23631283)

  • 21. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials.
    Fox K; Komajda M; Ford I; Robertson M; Böhm M; Borer JS; Steg PG; Tavazzi L; Tendera M; Ferrari R; Swedberg K
    Eur Heart J; 2013 Aug; 34(29):2263-70. PubMed ID: 23536611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of ivabradine and heart rate lowering in chronic heart failure: guideline update.
    Chow SL; Page RL; Depre C
    Expert Rev Cardiovasc Ther; 2018 Jul; 16(7):515-526. PubMed ID: 29902387
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease.
    DiFrancesco D; Camm JA
    Drugs; 2004; 64(16):1757-65. PubMed ID: 15301560
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Heart rate: a risk factor or an epiphenomenon?].
    Metra M; Zacà V; Lombardi C; Bugatti S; Dei Cas L
    G Ital Cardiol (Rome); 2010 Mar; 11(3):209-20. PubMed ID: 20550061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. β-Blockers and ivabradine differentially affect cardiopulmonary function and left ventricular filling index.
    Fischer-Rasokat U; Honold J; Lochmann D; Wolter S; Liebetrau C; Fichtlscherer S; Möllmann H; Spyridopoulos I; Hamm CW
    Clin Res Cardiol; 2016 Jun; 105(6):527-34. PubMed ID: 26687495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ivabradine in heart failure: hope or hype?
    Deedwania PC
    Am J Cardiovasc Drugs; 2012 Dec; 12(6):357-9. PubMed ID: 23181943
    [No Abstract]   [Full Text] [Related]  

  • 27. Ivabradine: an intelligent drug for the treatment of ischemic heart disease.
    Riccioni G
    Molecules; 2012 Nov; 17(11):13592-604. PubMed ID: 23159921
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heart rate in coronary syndromes and heart failure.
    Orso F; Baldasseroni S; Maggioni AP
    Prog Cardiovasc Dis; 2009; 52(1):38-45. PubMed ID: 19615492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Heart rate reduction: beneficial effects in heart failure and post-infarcted myocardium].
    Berdeaux A; Tissier R; Couvreur N; Salouage I; Ghaleh B
    Therapie; 2009; 64(2):87-91. PubMed ID: 19664401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical results with I(f) current inhibition by ivabradine.
    Berdeaux A
    Drugs; 2007; 67 Suppl 2():25-33. PubMed ID: 17999561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure.
    De Ferrari GM; Mazzuero A; Agnesina L; Bertoletti A; Lettino M; Campana C; Schwartz PJ; Tavazzi L
    Eur J Heart Fail; 2008 Jun; 10(6):550-5. PubMed ID: 18486549
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ivabradine: recent and potential applications in clinical practice.
    Riccioni G
    Expert Opin Pharmacother; 2011 Feb; 12(3):443-50. PubMed ID: 21254949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heart rate slowing for myocardial dysfunction/heart failure.
    Mulder P; Thuillez C
    Adv Cardiol; 2006; 43():97-105. PubMed ID: 16936475
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Beta-blockers and ivabradine in chronic heart failure: from clinical trials to clinical practice.
    Di Franco A; Sarullo FM; Salerno Y; Figliozzi S; Parrinello R; Di Pasquale P; Lanza GA
    Am J Cardiovasc Drugs; 2014 Apr; 14(2):101-10. PubMed ID: 24327100
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ivabradine treatment prevents dobutamine-induced increase in heart rate in patients with acute decompensated heart failure.
    Cavusoglu Y; Mert U; Nadir A; Mutlu F; Morrad B; Ulus T
    J Cardiovasc Med (Hagerstown); 2015 Sep; 16(9):603-9. PubMed ID: 24922198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical perspectives of heart rate slowing for coronary event reduction and heart failure.
    Danchin N; Kadri Z
    Adv Cardiol; 2006; 43():45-53. PubMed ID: 16936471
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The discovery of the selective I(f) current inhibitor ivabradine. A new therapeutic approach to ischemic heart disease.
    Vilaine JP
    Pharmacol Res; 2006 May; 53(5):424-34. PubMed ID: 16638639
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine.
    Canet E; Lerebours G; Vilaine JP
    Ann N Y Acad Sci; 2011 Mar; 1222():90-9. PubMed ID: 21434947
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A New Insight on Anti-Ischemic Action of Ivabradine in Patients With Stable Angina].
    Kobalava ZD; Shavarov AA; Kiyakbaev GK
    Kardiologiia; 2017 Mar; 57(3):68-74. PubMed ID: 28762939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heart rate reduction: a potential target for the treatment of myocardial ischaemia.
    Danchin N; Aly S
    Therapie; 2004; 59(5):511-5. PubMed ID: 15648303
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.